Propanc Biopharma, Inc. (PPCB) stock
PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$1.88−0.01 (-0.53%)
Close on Nov 17, 2026Market cap $1.85MP/E –Yield –
Propanc Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Propanc Biopharma's operating income for the twelve months ending Sep 30, 2026 was -$22.08M. For fiscal 2026 it was -$18.19M. The highest annual figure on record is -$761.22K in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$18.19M | – |
| FY2025 | Jun 30, 2025 | -$57.28M | – |
| FY2024 | Jun 30, 2024 | -$1.54M | – |
| FY2023 | Jun 30, 2023 | -$1.78M | – |
| FY2022 | Jun 30, 2022 | -$1.99M | – |
| FY2021 | Jun 30, 2021 | -$1.81M | – |
| FY2020 | Jun 30, 2020 | -$3.49M | – |
| FY2019 | Jun 30, 2019 | -$2.61M | – |
| FY2018 | Jun 30, 2018 | -$3.96M | – |
| FY2017 | Jun 30, 2017 | -$5.74M | – |
| FY2016 | Jun 30, 2016 | -$6.90M | – |
| FY2015 | Jun 30, 2015 | -$1.71M | – |
| FY2014 | Jun 30, 2014 | -$761.22K | – |
| FY2013 | Jun 30, 2013 | -$1.36M | – |
| FY2012 | Jun 30, 2012 | -$11.59M | – |
| FY2011 | Jun 30, 2011 | -$2.24M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$8.57M | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$3.46M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$6.40M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$3.65M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$4.67M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$3.65M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$53.13M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$213.38K | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$290.79K | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$259.90K | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$420.87K | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$438.06K | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$417.22K | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$209.60K | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$386.21K | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$608.00K | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$572.83K | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$599.19K | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$502.18K | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$403.47K | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$486.03K | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$726.94K | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$427.95K | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$274.09K | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$383.16K | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$594.07K | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$607.17K | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$1.38M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$909.42K | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$836.33K | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$571.73K | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$757.82K | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$448.87K | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$511.75K | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$807.14K | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$1.44M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$1.20M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$1.11M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$1.55M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$1.91M | – |
See a number that looks wrong?